Research and Development (“R&D”) Expenses: R&D expenses for the three months ended December 31, 2024, were $8.2 million, compared to $13.5 million for the same period in 2023. The decrease was due ...
In June 2024, Junshi Biosciences convened the 2023 annual general meeting, the 2024 first class meeting of A shareholders and the 2024 first class meeting of H shareholders, and completed the election ...
PARIS, 29 mars 2025 (GLOBE NEWSWIRE) -- Curium Pharma (“Curium”), leader mondial de la médecine nucléaire, annonce franchir un nouveau cap en achevant l’acquisition d’Eczacıbaşı-Monrol Nuclear ...
Safety Shot, Inc. (Nasdaq: SHOT) (the “Company” or “Safety Shot”), today announced that the record date for the spin-off and distribution of shares of common stock, par value $0.0001 per share, ...
WESTLAKE VILLAGE, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial ...
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by ...
Unique mechanism helps reduce the frequency of bleeding episodes for people with hemophilia ...
Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and chronic ...
In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...
BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...
Dr. Dukes has held leadership roles in public and private biopharmaceutical companies, leveraging vast experience in corporate, strategic and product development. Dr. Cautreels will continue in his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback